Attitudes and concerns regarding booster dose of COVID-19 vaccine among Egyptian patients with autoimmune and rheumatic diseases: a cross-sectional survey study

References

• Coleman KK, Tay DJW, Tan KS, Ong SWX, Than TS, Koh MH, et al.Viral load of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in respiratory aerosols emitted by patients with coronavirus disease 2019 (COVID-19) while breathing, talking, and singingClin Infect Dis20227417221728 1:CAS:528:DC%2BB38Xhs1ehs77F 10.1093/cid/ciab691 34358292
   PubMedGoogle Scholar
• Egypt: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2022 Dec 28]. Available from: https://covid19.who.int.
   Google Scholar
• El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR, Kenawy ERThree waves changes, new variant strains, and vaccination effect against COVID-19 pandemicInt J Biol Macromol2022204161168 1:CAS:528:DC%2BB38XivF2hs7w%3D 35074332 8782737 10.1016/j.ijbiomac.2022.01.118
   PubMed Web of Science ®Google Scholar
• Asem N, Ramadan A, Hassany M, Ghazy RM, Abdallah M, Ibrahim M, et al.Pattern and determinants of COVID-19 infection and mortality across countries: an ecological studyHeliyon20217 1:CAS:528:DC%2BB38XitVKhsLrM 34254048 8264269 10.1016/j.heliyon.2021.e07504
   PubMed Web of Science ®Google Scholar
• Lenzen M, Li M, Malik A, Pomponi F, Sun Y-Y, Wiedmann T, et al.Global socio-economic losses and environmental gains from the Coronavirus pandemicPLoS ONE202015 10.1371/journal.pone.0235654 32645023 7347123
   PubMed Web of Science ®Google Scholar
• Impact of COVID-19 vaccination on the risk of SARS-CoV-2 infection and hospitalization and death in Italy (27.12.2020–14.07.2021). English version of the ISS report-ISS (EN)-ISS [Internet]. ISS EN. [cited 2022 Dec 26]. Available from: https://iss.it/web/iss-en/highlighted/-/asset_publisher/0JjjK4TivXZp/content/impact-of-covid-19-vaccination-on-the-risk-of-sars-cov-2-infection-and-hospitalization-and-death-in-italy-27.12.2020-14.07.2021.
   Google Scholar
• Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus Pandemic (COVID-19). Our World Data [Internet]. 2020 [cited 2022 Dec 29]; Available from: https://ourworldindata.org/coronavirus.
   Google Scholar
• Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al.Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 monthsN Engl J Med2021385 1:CAS:528:DC%2BB3MXislKlsbrN 34614326 10.1056/NEJMoa2114583
   PubMed Web of Science ®Google Scholar
• Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar|NEJM. https://doi.org/10.1056/nejmoa2114114.
   Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al.Protection of BNT162b2 vaccine booster against Covid-19 in IsraelN Engl J Med202138513931400 1:CAS:528:DC%2BB3MXit1SgurnE 10.1056/NEJMoa2114255 34525275
   PubMed Web of Science ®Google Scholar
• Parker EPK, Desai S, Marti M, Nohynek H, Kaslow DC, Kochhar S, et al.Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid reviewLancet Glob Health202210e326e328 1:CAS:528:DC%2BB3sXislSiu7Y%3D 35180408 8846615 10.1016/S2214-109X(21)00593-3
   PubMed Web of Science ®Google Scholar
• Wieske L, van Dam KPJ, Steenhuis M, Stalman EW, Kummer LYL, van Kempen ZLE, et al.Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLancet Rheumatol20224e338e350 1:CAS:528:DC%2BB3sXis1ygsrw%3D 35317410 8930018 10.1016/S2665-9913(22)00034-0
   PubMedGoogle Scholar
• Furlow BImmunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccineLancet Rheumatol.20213 1:CAS:528:DC%2BB3sXis1yitbs%3D 34608457 8482527 10.1016/S2665-9913(21)00313-1
   PubMedGoogle Scholar
• Gil-Vila A, Ravichandran N, Selva-O’Callaghan A, Sen P, Nune A, Gaur PS, et al.COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: vaccine safety in idiopathic inflammatory myopathiesMuscle Nerve202266426437 1:CAS:528:DC%2BB38Xit1enu7jI 35869701 9349921 10.1002/mus.27681
   PubMed Web of Science ®Google Scholar
• Sen P, Ravichandran N, Nune A, Lilleker JB, Agarwal V, Kardes S, et al.COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD studyRheumatol Oxf Engl2022626576 10.1093/rheumatology/keac305
   PubMed Web of Science ®Google Scholar
• MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, et al.Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platformLancet Rheumatol20224e490506 1:CAS:528:DC%2BB3sXis1yjtb0%3D 35698725 9179144 10.1016/S2665-9913(22)00098-4
   PubMedGoogle Scholar
• Sen. Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study [Internet]. [cited 2023 Feb 27]. Available from: https://indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=2;spage=188;epage=191;aulast=Sen;type=3.
   Google Scholar
• Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, et al.Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine surveyRheumatol Oxf Engl.202261143150 10.1093/rheumatology/keac249
   Web of Science ®Google Scholar
• Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, et al.Immunogenicity and safety of standard and third-dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapyArthritis Rheumatol Hoboken NJ20227413211332 1:CAS:528:DC%2BB38XitF2jsrfJ 10.1002/art.42153
   PubMed Web of Science ®Google Scholar
• Farroni C, Aiello A, Picchianti-Diamanti A, Laganà B, Petruccioli E, Agrati C, et al.Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: a prospective multicenter longitudinal studyInt J Infect Dis2022125195208 1:CAS:528:DC%2BB38XivFOnt7%2FO 36328289 9622025 10.1016/j.ijid.2022.10.035
   PubMedGoogle Scholar
• Sallam M, Al-Sanafi M, Sallam MA global map of COVID-19 vaccine acceptance rates per country: an updated concise narrative reviewJ Multidiscip Healthc2022152145 35046661 8760993 10.2147/JMDH.S347669
   PubMed Web of Science ®Google Scholar
• Aw J, Seng JJB, Seah SSY, Low LLCOVID-19 vaccine hesitancy-a scoping review of literature in high-income countriesVaccines20219900 1:CAS:528:DC%2BB3MXitVGrs77L 34452026 8402587 10.3390/vaccines9080900
   PubMed Web of Science ®Google Scholar
• Wong LP, Alias H, Siaw Y-L, Muslimin M, Lai LL, Lin Y, et al.Intention to receive a COVID-19 vaccine booster dose and associated factors in MalaysiaHum Vaccines Immunother2022182078634 10.1080/21645515.2022.2078634
   PubMed Web of Science ®Google Scholar
• Tokiya M, Hara M, Matsumoto A, Ashenagar MS, Nakano T, Hirota YAcceptance of booster COVID-19 vaccine and its association with components of vaccination readiness in the general population: a cross-sectional survey for starting booster dose in JapanVaccines2022101102 1:CAS:528:DC%2BB38XitVOqsrfJ 35891266 9323594 10.3390/vaccines10071102
   PubMed Web of Science ®Google Scholar
• Lai X, Zhu H, Wang J, Huang Y, Jing R, Lyu Y, et al.Public perceptions and acceptance of COVID-19 booster vaccination in China: a cross-sectional studyVaccines202191461 1:CAS:528:DC%2BB38XkvFGktLg%3D 34960208 8709447 10.3390/vaccines9121461
   PubMed Web of Science ®Google Scholar
• Frontiers|COVID-19 vaccine booster hesitancy (VBH) of healthcare professionals and students in Poland: Cross-sectional survey-based study. https://doi.org/10.3389/fpubh.2022.938067/full.
   Google Scholar
• Gliem JA, Gliem RR. Calculating, interpreting, and reporting Cronbach’s alpha reliability coefficient for likert-type scales. Midwest Research-to-Practice Conference in Adult, Continuing, and Community Education; 2003; Available from: https://scholarworks.iupui.edu/handle/1805/344
   Google Scholar
• World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJAMA201331021912194 10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Galanis P, Vraka I, Katsiroumpa A, Siskou O, Konstantakopoulou O, Katsoulas T, et al.First COVID-19 booster dose in the general population: a systematic review and meta-analysis of willingness and its predictorsVaccines2022101097 1:CAS:528:DC%2BB38XitVOqs77K 35891260 9323526 10.3390/vaccines10071097
   PubMed Web of Science ®Google Scholar
• Yadete T, Batra K, Netski DM, Antonio S, Patros MJ, Bester JCAssessing acceptability of COVID-19 vaccine booster dose among adult Americans: a cross-sectional studyVaccines202191424 1:CAS:528:DC%2BB38XlvVSmtw%3D%3D 34960170 8703732 10.3390/vaccines9121424
   PubMed Web of Science ®Google Scholar
• Speer C, Töllner M, Benning L, Klein K, Bartenschlager M, Nusshag C, et al.Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitisAnn Rheum Dis202281593595 1:CAS:528:DC%2BB38XosVGksrs%3D 35012926 10.1136/annrheumdis-2021-221747
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Karamanakos A, Arida A, Bournia V-K, Evangelatos G, Fanouriakis A, et al.Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseasesRMD Open20228e002279 10.1136/rmdopen-2022-002279 35246472
   PubMed Web of Science ®Google Scholar
• Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, et al.SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statementLancet Gastroenterol Hepatol20216218224 33508241 7834976 10.1016/S2468-1253(21)00024-8
   PubMed Web of Science ®Google Scholar
• Al-Qerem W, Al Bawab AQ, Hammad A, Ling J, Alasmari FWillingness of the Jordanian population to receive a COVID-19 booster dose: a cross-sectional studyVaccines202210410 1:CAS:528:DC%2BB38XhtVOntr3K 35335042 8950968 10.3390/vaccines10030410
   PubMed Web of Science ®Google Scholar
• Babicki M, Mastalerz-Migas AAttitudes of poles towards the COVID-19 vaccine booster dose: an online survey in PolandVaccines20221068 1:CAS:528:DC%2BB38XntV2jtL8%3D 35062729 8778409 10.3390/vaccines10010068
   PubMedGoogle Scholar
• Cunha R, Ochoa-Leite C, Pires L, Morais M, Costa R, Rocha LCOVID-19 vaccine booster in healthcare workers—reasons for refusingPulmonology202228476477 1:STN:280:DC%2BB2Mvgt1Omuw%3D%3D 35351400 8882415 10.1016/j.pulmoe.2022.02.007
   PubMed Web of Science ®Google Scholar
• Abu-Farha R, Mukattash T, Itani R, Karout S, Khojah HMJ, Abed Al-Mahmood A, et al.Willingness of Middle Eastern public to receive COVID-19 vaccinesSaudi Pharm J SPJ Off Publ Saudi Pharm Soc202129734739 1:CAS:528:DC%2BB3MXhtlegtL%2FM
   PubMed Web of Science ®Google Scholar
• Kaadan MI, Abdulkarim J, Chaar M, Zayegh O, Keblawi MADeterminants of COVID-19 vaccine acceptance in the Arab world: a cross-sectional studyGlob Health Res Policy.2021623 10.1186/s41256-021-00202-6 34253254 8273556
   PubMedGoogle Scholar
• Qunaibi EA, Helmy M, Basheti I, Sultan IA high rate of COVID-19 vaccine hesitancy in a large-scale survey on ArabsElife202110e68038 1:CAS:528:DC%2BB3MXislSku7%2FN 10.7554/eLife.68038 34042047 8205489
   PubMed Web of Science ®Google Scholar
• Preliminary public health considerations for COVID-19 vaccination strategies in the second half of 2022 [Internet]. Eur. Cent. Dis. Prev. Control. 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/preliminary-public-health-considerations-covid-19-vaccination-strategies-second.
   Google Scholar
• Nguyen DC, Dao TL, Truong TMD, Nguyen TH, Phan TN, Nguyen HM, et al.Short-term adverse effects immediately after the start of COVID-19 booster vaccination in VietnamVaccines2022101325 1:CAS:528:DC%2BB38XitlWrs7fK 36016213 9414515 10.3390/vaccines10081325
   PubMedGoogle Scholar
• Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atluri PReview of COVID-19 variants and COVID-19 vaccine efficacy: what the clinician should know?J Clin Med Res202113317325 1:CAS:528:DC%2BB3MXitlejsLbO 34267839 8256910 10.14740/jocmr4518
   PubMedGoogle Scholar
• Tanne JHCovid-19: moderna plans booster doses to counter variantsBMJ2021372 33500251 10.1136/bmj.n232
   PubMedGoogle Scholar
• Lounis M, Bencherit D, Rais MA, Riad ACOVID-19 vaccine booster hesitancy (VBH) and its drivers in Algeria: national cross-sectional survey-based studyVaccines202210621 1:CAS:528:DC%2BB38Xht1SrtLrJ 35455371 9031698 10.3390/vaccines10040621
   PubMed Web of Science ®Google Scholar
• Rzymski P, Poniedziałek B, Fal AWillingness to receive the booster COVID-19 vaccine dose in PolandVaccines202191286 1:CAS:528:DC%2BB3MXis1OgtrvJ 34835217 8624071 10.3390/vaccines9111286
   PubMed Web of Science ®Google Scholar
• Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Avihingsanon Y, et al.Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritisLupus Sci Med.20229e000726 10.1136/lupus-2022-000726 35902168
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al.Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variantsJAMA2022327639651 1:CAS:528:DC%2BB38XktFSgsLY%3D 35060999 8848203 10.1001/jama.2022.0470
   PubMed Web of Science ®Google Scholar
• Cerqueira-Silva T, Katikireddi SV, de Araujo OV, Flores-Ortiz R, Júnior JB, Paixão ES, et al.Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in BrazilNat Med202228838843 1:CAS:528:DC%2BB38XjtlSgurw%3D 35140406 9018414 10.1038/s41591-022-01701-w
   PubMed Web of Science ®Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al.Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccinationNat Med202228481485 35051990 8938264 10.1038/s41591-022-01705-6
   PubMed Web of Science ®Google Scholar
• Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al.Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohortAnn Rheum Dis20218013061311 1:CAS:528:DC%2BB3MXit1KlsbbM 33762264 10.1136/annrheumdis-2021-220272
   PubMed Web of Science ®Google Scholar
• Priori R, Pellegrino G, Colafrancesco S, Alessandri C, Ceccarelli F, Di Franco M, et al.SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologistsAnn Rheum Dis202180953954 1:CAS:528:DC%2BB3MXhvVOjtr3I 33622689 10.1136/annrheumdis-2021-220059
   PubMedGoogle Scholar
• Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al.Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variantN Engl J Med202238615321546 1:CAS:528:DC%2BB38XhtFGrsLbN 35249272 10.1056/NEJMoa2119451
   PubMed Web of Science ®Google Scholar
• Chenchula S, Karunakaran P, Sharma S, Chavan MCurrent evidence on efficacy of COVID-19 booster dose vaccination against the omicron variant: a systematic reviewJ Med Virol20229429692976 1:CAS:528:DC%2BB38XntFeqtr0%3D 35246846 9088621 10.1002/jmv.27697
   PubMed Web of Science ®Google Scholar
• Paul E, Steptoe A, Fancourt DAttitudes towards vaccines and intention to vaccinate against COVID-19: implications for public health communicationsLancet Reg Health Eur20211 33954296 10.1016/j.lanepe.2020.100012
   PubMedGoogle Scholar
• Bogart LM, Ojikutu BO, Tyagi K, Klein DJ, Mutchler MG, Dong L, et al.COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among black Americans living with HIVJ Acquir Immune Defic Syndr1999202186200207
   Google Scholar
• Sallam MCOVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance ratesVaccines20219160 1:CAS:528:DC%2BB3MXitVSmu7fL 33669441 7920465 10.3390/vaccines9020160
   PubMed Web of Science ®Google Scholar